Wells Fargo & Company MN Acquires 81,144 Shares of Edwards Lifesciences Co. (NYSE:EW)

Wells Fargo & Company MN lifted its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 10.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 844,023 shares of the medical research company's stock after buying an additional 81,144 shares during the period. Wells Fargo & Company MN owned approximately 0.14% of Edwards Lifesciences worth $62,483,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Prudential PLC lifted its holdings in shares of Edwards Lifesciences by 0.5% during the fourth quarter. Prudential PLC now owns 213,369 shares of the medical research company's stock valued at $15,796,000 after purchasing an additional 1,057 shares during the last quarter. Thoroughbred Financial Services LLC boosted its holdings in shares of Edwards Lifesciences by 2.4% in the fourth quarter. Thoroughbred Financial Services LLC now owns 19,545 shares of the medical research company's stock worth $1,446,000 after buying an additional 465 shares during the period. ExodusPoint Capital Management LP purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $2,253,000. Arete Wealth Advisors LLC raised its holdings in shares of Edwards Lifesciences by 20.4% during the fourth quarter. Arete Wealth Advisors LLC now owns 4,139 shares of the medical research company's stock valued at $307,000 after acquiring an additional 700 shares during the period. Finally, Cinctive Capital Management LP boosted its stake in Edwards Lifesciences by 166.1% in the 4th quarter. Cinctive Capital Management LP now owns 148,923 shares of the medical research company's stock worth $11,025,000 after purchasing an additional 92,963 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.72 during midday trading on Monday, hitting $70.12. 470,451 shares of the company were exchanged, compared to its average volume of 4,897,024. The firm's 50 day moving average price is $71.32 and its two-hundred day moving average price is $70.74. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $41.22 billion, a P/E ratio of 10.06, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Truist Financial dropped their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday. Finally, Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $78.55.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,853 shares of company stock valued at $4,534,247 in the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.